Immunoglobulin A Nephropathy study: ARGX-121
Official title A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
ClinicalTrials.gov ID: NCT07773727
What this study is testing
What is ARGX-121?
ARGX-121 is an investigational once‑daily subcutaneous injectable medicine being studied for immunoglobulin A nephropathy (IgAN).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether ARGX‑121 can improve kidney health in people with IgA nephropathy. It looks at how the drug is processed by the body and how the immune system reacts.
- Who it's for
- You may be able to join if you are an adult with IgA nephropathy and are already receiving regular treatment for it.
- What's involved
- You will keep taking your usual medicines while the study runs. You will receive the study drug or a pretend treatment during a period where neither you nor the doctors know which you get. After that, you will receive the real drug for up to a year. You will have regular visits for tests and check‑ins.
- Time commitment
- The study lasts about 72 weeks, with up to 52 weeks of the real drug. You will need to attend several clinic visits during that time.
- Phase 2: a mid-size study of how well it works
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Males and females (not pregnant)
- At least 18 years old
- Clinically diagnosed with IgAN with biopsy confirmation
You likely can't join if
- Diagnosis of another autoimmune disease or known medical condition that would interfere with accurate assessment of clinical systems of IgAN
- Has secondary form of IgAN leading to IgA deposits
- History of Malignancy
- Active infection of concern
- Recent Major surgery or organ transplant
The study team makes the final eligibility decision.
Where it is enrolling
- Valencia, California, United States
- Miami, Florida, United States
- Pembroke Pines, Florida, United States
- Pontiac, Michigan, United States
- Houston, Texas, United States
- Salt Lake City, Utah, United States
- Manassas, Virginia, United States
- Fukuoka, Fukuoka, Japan
- Sapporo, Hokkaidô, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Valencia, California, United States; Miami, Florida, United States; Pembroke Pines, Florida, United States; Pontiac, Michigan, United States; Houston, Texas, United States; Salt Lake City, Utah, United States and 3 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.